Numerous studies have demonstrated a significantly higher number of CD68+ macrophages and CD163+ M2-like phenotypes in the tumor mass and within infiltrative areas of glioblastoma patient post-bevacizumab therapy [38–41]. This evidence concerns the gene CD163 and neoplasm.